Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

July 2, 2013

Liver toxins delay CT Achillion's hep C trial

Courtesy photo Achillion CEO Milind S. Deshpande

Achillion Pharmaceuticals Inc. got a dose of bad news about its efforts to develop a treatment for hepatitis C.

The New Haven biopharmaceutical company said Monday the U.S. Food & Drug Administration suspended one of its clinical trials for its hepatitis C drug sovaprevir after a trial subject built up an unusually high amount of toxic liver enzymes.

Despite the setback, however, the FDA is allowing Achillion to continue enrollment and the 12-week treatment of patients in Phase 2 trials involving sovaprevir and Achillion's ACH-3102 formulation, the company said.

The company was due to elaborate on the FDA notification and other clinical-trial data during a Monday afternoon conference call with financial analysts and reporters.

Sign up for Enews

Related Content

0 Comments

Order a PDF